50 results about "Liver toxicity" patented technology

The application discloses a compound Chinese herbal medicine fermentation preparation for preventing and treating hepatotoxicity of Penaeus vannamei and a preparation method thereof. Spore bacillus is used as a fermentation strain to perform aerobic fermentation on four traditional Chinese herbal medicine stem and leaf wastes, i.e. Astragalus stem and leaf, Rhubarb stem and leaf, Codonopsis stem and leaf and Coptis stem and leaf, so as to obtain a compound Chinese herbal medicine fermentation product with higher active substances. The compound Chinese herbal medicine fermentation preparation of the application can be added into the feed of Penaeus vannamei, so as to effectively prevent and treat hepatotoxicity of Penaeus vannamei.

The invention discloses a medicine for preventing or treating liver toxic and side effects of osimertinib, and belongs to the technical field of medicines. Aiming at liver toxic and side effects caused by osimertinib, the invention provides an effective therapeutic drug, and the autophagy inhibitor relieves death caused by excessive activation of an autophagy pathway in hepatocytes by inhibiting autophagy activated by osimertinib, so that hepatotoxicity caused by osimertinib is relieved. The autophagy inhibitor and osimertinib are combined, so that the survival rate of hepatocytes can be remarkably improved, and liver injury caused in the osimertinib treatment process is reduced. The invention further provides novel application of the hydroxychloroquine or the S-adenosylmethionine in preparation of the medicine for preventing or treating the liver toxic and side effects of the osimertinib, the hydroxychloroquine or the S-adenosylmethionine has a remarkable treatment effect on liver injuries caused by the osimertinib, the medication safety of the hydroxychloroquine or the S-adenosylmethionine is high, and the hydroxychloroquine or the S-adenosylmethionine can be used for preparing the medicine for preventing or treating the liver toxic and side effects of the osimertinib. Good development prospects are realized.

The invention provides a tripterine sulfated metabolite and application thereof in preparation of a medicine for resisting rheumatoid arthritis, and belongs to the technical field of biological medicine. The tripterine sulfated metabolite is 10-sulfated tripterine which is formed by connecting a HSO3 <-> to the 10-position carbon of the tripterine. Compared with the tripterine, the 10-sulfonated tripterine has no obvious difference in anti-rheumatoid arthritis pharmacological activity, however, the hepatotoxicity in vivo and the cytotoxicity in vitro of the 10-sulfonated tripterine are obviously reduced. The tripterine sulfated metabolite is efficient and low in toxicity, and a wide application prospect is developed for treatment of rheumatoid arthritis.

The invention discloses a lipid-lowering and weight-losing composition with homology of medicine and food as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. The composition for reducing fat and losing weight comprises the following raw materials in parts by weight: 10-40 parts of lotus leaves, 20-50 parts of haws, 15-45 parts of poria cocos, 5-35 parts of dried orange peel, 60-130 parts of raspberries, 0-15 parts of fingered citron and 0-15 parts of kudzuvine roots. Compared with a model group, the fat-reducing and weight-losing composition disclosed by the invention has the advantages that the weight of a mouse can be reduced by 12%-15%, the serum total cholesterol level and the leptin level are reduced, the number of fat cells per unit area is increased, the liver adiposis symptom is obviously improved, the expression of heat production factors in epididymal fat and groin fat is up-regulated, and liver toxicity is avoided. The raw materials of the composition for reducing fat and losing weight are all traditional Chinese medicines with homology of medicine and food, so that the composition has no obvious damage to organisms and is safer; the fat-reducing and weight-losing composition can achieve a good weight-losing effect by compounding the raw materials.

The present invention discloses a method for analyzing the liver toxicity differences between proton pump inhibitors and H2 receptor antagonists based on network toxicology. The method of the present invention comprises the following steps: mining the action targets of drugs and liver toxicity disease risk genes in a database, constructing a protein interaction network of the drug-induced liver injury disease module DILI, and performing GO biological function and KEGG pathway enrichment analysis on the risk genes; overlapping the drug targets and the DILI disease module and analyzing the drug liver toxicity mechanism; calculating the proximity degree between the drug and the DILI disease module by using a network proximity strategy; and finally performing molecular docking on the drug molecule and the core target. The method of the present invention reveals that H2 receptor antagonists have stronger liver toxicity than proton pump inhibitors, explores the mechanism of potential liver injury of drugs, and provides a reference for the subsequent liver toxicity research of drugs.

The invention discloses a steroid phosphate ester compound, a pharmaceutically acceptable salt, a tautomer, a preparation method of the steroid phosphate ester compound, the pharmaceutically acceptable salt, the tautomer, the preparation method of the steroid phosphate ester compound, the pharmaceutical composition and application of the steroid phosphate ester compound, and the steroid phosphate ester compound is a compound almost free of hepatotoxicity and can be used for preventing and treating androgen receptor related diseases such as prostatic cancer. Specifically, the invention relates to a steroid phosphate compound represented by a formula (I) or a pharmaceutically acceptable salt thereof, wherein the definition of each substituent is shown in the specification. # imgabs0 #

Systems and methods consistent with the present invention generally relate to microorganospheres (MOSs), and methods and apparatuses for forming and using MOSs. More particularly, in some embodiments, systems and methods consistent with the invention relate to the methods and apparatuses for forming and using MOSs generated from hepatocytes. MOPSs that are generated from hepatocytes are suitable for testing liver toxicity and drug induced liver injury effects of various agents.

The present invention discloses a method and device for predicting changes in the content of a drug in a living body. The present invention uses microsomes to construct a kinetic reaction system of a test substance in vitro, allowing the test substance to fully react in the microsomes, and determining the reaction conditions for conducting in vitro kinetic experiments using microsomes. Through the constructed microsomal reaction system, the metabolic rate of the test substance in the liver and / or small intestine of the living body is calculated, and its metabolic kinetic parameters are written into calculus equations using a computer, and then solved to finally obtain the kinetic process of the test substance, thereby making up for the shortcomings of conducting toxicity experiments using in vitro biological tissues. The present invention can analyze the toxicity characteristics of drugs in the liver of mice and predict the dose that produces liver toxicity without the need for animal experiments.

The application relates to an application of a SETDB1 activator in a medicine for treating organ injury and the medicine. The application of the SETDB1 activator in the medicine for treating organ injury is (R, R)-59. The application further provides a medicine for treating organ injury, and the medicine comprises the SETDB1 activator (R, R)-59. The application provides a new application of the SETDB1 activator (R, R)-59, and the SETDB1 activator (R, R)-59 can effectively relieve liver toxicity caused by hunger or other factors by regulating lipid toxicity and promoting lipid autophagy, the SETDB1 activator (R, R)-59 can inhibit inflammatory response and hepatocyte apoptosis caused by APAP overdose, promotes liver repair, and provides a new medicine for treating drug-induced liver injury.

The invention belongs to the technical field of traditional Chinese medicine preparations, and provides anti-cold granules and a preparation method thereof. The preparation method comprises the following steps: (1) preparing an extract: performing ultrasonic water extraction on honeysuckle flower powder to obtain a honeysuckle flower extract; performing ultrasonic extraction on the radix paeoniae rubra powder by adopting a composite solvent to obtain a radix paeoniae rubra water extract; adding a natural clarifying agent into the red paeony root water extract for clarifying, cooling, filtering, and concentrating under reduced pressure to obtain a red paeony root extract; carrying out ultrasonic water extraction on rhizoma dryopteris crassirhizomae, filtering, and carrying out vacuum concentration to obtain a rhizoma dryopteris crassirhizomae extract; (2) mixing the honeysuckle extract, the radix paeoniae rubra extract and the rhizoma dryopteris crassirhizomae extract, and performing vacuum concentration to obtain clear paste; and adding auxiliary materials into the clear paste to prepare the anti-cold granules. By adopting the preparation method, the dissolution of effective components in the anti-cold granules can be remarkably improved, and particularly the contents of paeoniflorin and chlorogenic acid are increased, so that the liver toxicity generated by the medicinal component phloroglucinol derivative of the rhizoma dryopteris crassirhizomae is balanced, and the effects of reducing toxicity and enhancing efficiency are achieved.

The present invention discloses the use of a short-term embolic agent in reducing drug accumulation in the liver, hepatic clearance and / or liver toxicity. The present invention provides the use of a short-term embolic agent in the manufacture of a medical composition for: (a) temporarily embolizing blood vessels supplying the liver; and (b) reducing the accumulation of a drug subsequently or concurrently administered intravenously in the liver. The strategy aims to minimize the exposure of a drug (such as LNP) to the liver by temporarily blocking the blood supply to the liver via the portal vein and / or arteries. The present invention significantly reduces the non-specific accumulation of a drug in the liver by temporarily blocking the portal vein, arterial and / or their branch blood flow, thereby greatly reducing the opportunity for the drug to enter the liver from a hemodynamic root.

The invention discloses a novel TNF-alpha targeted protein degradation agent for treating acute hepatic failure, the TNF-alpha targeted protein degradation agent can accurately remove excessive TNF-alpha to block a liver injury signal, and the defects that a traditional TNF-alpha inhibitor interferes tissue repair due to an overlong half-life period and an Fc fragment triggers an ADCC / CDC effect to cause drug-related hepatotoxicity are overcome. The pharmaceutical safety is improved while the treatment effectiveness is ensured, a better treatment choice is provided for acute hepatic failure and other TNF-alpha related diseases, and the pharmaceutical composition has a good clinical application prospect and an important conversion value.

The invention discloses a construction method of a three-dimensional liver micro-tissue model and hepatotoxicity assessment application of the three-dimensional liver micro-tissue model, and belongs to the technical field of environmental science and engineering. The 3D liver micro-tissue model constructed by the invention consists of three cell lines, namely HepaRG (parenchymal hepatic cells), THP-1 (kupffer cells) and hTERT-HSC (hepatic stellate cells), so that a real liver environment can be better simulated, and the defects of a traditional model are overcome; particularly, the occurrence of hepatic fibrosis relates to complex interaction among a plurality of cell lines, however, most of the previous models for evaluating the potential of hepatic fibrosis by chemical substances are lack of consideration of interaction among multiple types of cells no matter whether hepatic parenchymal cell lines or hepatic stellate cell lines are used, and the 3D hepatic micro-tissue model takes the factor into account, so that the potential of hepatic fibrosis cannot be evaluated. Key hepatic fibrosis events caused by hepatic fibrosis substances can be copied, and a more suitable test platform is provided for evaluating the potential of chemical substance hepatic fibrosis.

The application relates to a method and system for establishing a prediction model of chemical liver toxicity, which comprises the following steps: (1) differentiating human embryonic stem cells or human induced pluripotent stem cells into hepatocyte-like cells and constructing a three-dimensional hepatocyte model; (2) taking miR-122, LDH and Cyto C in the three-dimensional hepatocyte as combined test indexes to judge liver toxicity of a liver toxicity mode compound; (3) classifying the liver toxicity mode compound into three categories through two canonical discriminant functions by a linear discriminant analysis modeling method; and (4) converting the canonical discriminant function into a Fishers discriminant function to obtain a liver toxicity prediction model. The application has the general characteristics of a conventional cell model for evaluating compounds, and can also evaluate the toxicity effect and health risk of the compounds in a high-throughput manner with relatively less manpower.

The invention discloses Chinese wolfberry fruit composite puree, a preparation method thereof and application of the Chinese wolfberry fruit composite puree in preparation of a preparation for relieving cyclophosphamide toxicity, and relates to the technical field of traditional Chinese medicine combination medicines. Fresh Chinese wolfberry fruits and Chinese wolfberry fruit seed oil are used as main components of the Chinese wolfberry fruit composite puree. Experimental results show that the Chinese wolfberry fruit composite raw stock has an effect of relieving toxicity caused by cyclophosphamide, has a better curative effect than single use of Chinese wolfberry fruits, can effectively enhance the muscle strength of mice, enables aspartate transaminase (AST) and glutamic-pyruvic transaminase (ALT) with abnormally increased vitality to return to normal, resists abnormal swelling of the liver, relieves hepatotoxicity, improves the defense function of the body, and has a good application prospect. Therefore, the mouse death condition caused by cyclophosphamide poisoning is improved. The Chinese wolfberry fruit puree belongs to a health-care product, has the advantages of definite components and safety, and provides a new strategy and means for intervention and treatment of side effects caused by chemotherapy for tumor patients.

The invention belongs to the field of mRNA drugs, and particularly relates to an NQO1 responsive mRNA translation masking agent and application, a product and a method thereof. The molecular formula of the mRNA translation masking agent is C21H28N4O4, and the molecular formula of the mRNA translation masking agent is The mRNA translation masking agent can be covalently bound with mRNA through an acylation reaction to form steric hindrance inhibition translation, and efficiently recover the translation ability in an NQO1 high expression environment, so that the half-life period of mRNA in cells is prolonged, and the cumulative yield of target protein is also improved. The mRNA translation masking agent and the mRNA masking method thereof provided by the invention can be used for tumor targeted therapy, not only realizes specific removal of tumor cells, but also reduces hepatotoxicity. The technical scheme of the invention is helpful for developing safe, convenient and sensitive mRNA drugs for tumor targeted therapy.

Methods and uses are disclosed for treating a subject suffering from a disorder selected from a liver disorder, Cushing's syndrome, or Cushing's Disease, cancer, an infection, an inflammatory condition, a cardiovascular, endocrine, or kidney disease, and combinations thereof, or other disorder for which they may be administered a drug which may cause liver toxicity, without adverse effects on the liver. Such liver disorders include fatty liver diseases are effective for reducing high levels of liver enzymes with a favorable safety profile. The methods and uses comprise administering to the subject an effective amount of a selective nonsteroidal glucocorticoid receptor modulator such as relacorilant, including methods and uses in combination with another drug, without adverse effects on liver enzyme levels, or on liver function. In embodiments, the other drug may be a drug that may cause liver toxicity, such as drugs that inhibit CYP3A enzymes, e.g., itraconazole or ketoconazole.

The invention discloses a multi-modal hepatotoxicity prediction model determination method, and belongs to the technical field of big data processing. The method comprises the following steps: acquiring a drug-determination matrix of N rows and M columns, wherein the N rows comprise drug data of N drugs; the M column comprises measurement data of whether the medicine has a biological activity label or not under each target of the M targets; mapping K candidate determination data related to hepatotoxicity and F basic hepatotoxicity mechanism frameworks in the drug-determination matrix to obtain a biological fingerprint; determining heterogeneous data corresponding to each drug according to the chemical structure chart and the biological fingerprint of each drug in the N drugs; according to the drug data and the heterogeneous data of each drug, training the neural network prediction model until a preset training condition is met, and obtaining a multi-modal hepatotoxicity prediction model. Therefore, the cost of determining the hepatotoxicity of the compound can be effectively reduced without depending on experimental animals and manual operation, and the efficiency and accuracy of determining the hepatotoxicity of the compound are improved.

The invention belongs to the technical field of medicines, and particularly relates to itraconazole transdermal cream and a preparation method thereof. According to the itraconazole transdermal cream provided by the invention, the itraconazole and the clove essential oil are jointly applied by adopting an emulsification method, the limitation of single use of the itraconazole and the clove essential oil is broken through, the bioavailability of the itraconazole and the clove essential oil is improved, and the itraconazole transdermal cream acts on an infected part after being subjected to transdermal absorption through local administration, so that the itraconazole is absorbed into blood and reaches the skin of the whole body to play a role; the traditional Chinese medicine composition can achieve the same blood concentration and effect of oral administration, is convenient to use, reduces liver toxicity and gastrointestinal tract adverse reactions, and reduces the risk of adverse reactions and drug interaction at the same time.

The application discloses a vortioxetine impurity, a preparation method and application thereof, and adopts vortioxetine or a pharmaceutically acceptable salt form thereof as raw material, the raw material is easy to obtain and simple to operate, and the reaction condition is mild. The synthesized impurity is characterized by nuclear magnetic resonance, high-resolution mass spectrometry and X-ray single crystal diffraction, and liver toxicity research shows that the compound disclosed by the application has important significance for researching adverse reactions of vortioxetine. The control sample obtained by the method provided by the application can be used for qualitative and quantitative analysis of the vortioxetine impurity, so that the drug safety of vortioxetine is improved.

The application relates to the technical field of pharmaceutical preparations, and discloses an agomelatine inhalant as well as a preparation method and application thereof. The agomelatine inhalant provided by the application comprises agomelatine or a pharmaceutically acceptable salt thereof in a form capable of being inhaled or capable of being changed into a form capable of being inhaled after being excited. From the aspect of synergism, the inhalant can avoid first-pass metabolism by changing a drug administration route, significantly improve bioavailability, and realize rapid effect by directly entering blood from the lung; from the aspect of attenuation, the inhalant can greatly reduce a drug usage amount to achieve a same treatment effect as a tablet, significantly reduce occurrence of drug toxic and side reactions, and significantly reduce liver toxicity by avoiding liver metabolism.

The invention discloses application of ligusticum wallichii and a ligusticum wallichii extract in fish feed, and particularly relates to application of ligusticum wallichii powder or the ligusticum wallichii extract added in the fish feed in accelerating fish growth, reducing fish fat content, increasing body protein content, improving fish nutrition metabolism level and improving fish oxidation resistance. The invention solves the technical problem that the balance of fish protein and fat cannot be considered at the same time in the conventional fish feed feeding. Feeding pellet feed added with ligusticum wallichii powder and extract has no liver toxicity to the crucian carp; under the condition that the body weight is not reduced, the ligusticum wallichii powder and the extract can reduce the fat content of the fish, meanwhile, the protein content of the fish is increased, and the absorption function and lipid metabolism of the fish body are promoted. The ligusticum wallichii powder and the extract have a protective effect on the pellet feed, and a thought is provided for research and development of the fish feed which has a lipid-lowering effect and does not reduce the body weight of the fish.

The invention discloses a microfluidic device and a use method thereof, and relates to the technical field of microfluidics, the microfluidic device comprises a culture substrate unit, a first cell accommodating unit, a second cell accommodating unit and an interactive interface unit, the interactive interface unit is fixedly arranged between the first cell accommodating unit and the second cell accommodating unit, and the first cell accommodating unit is connected with the second cell accommodating unit. The interactive interface unit comprises a microporous structure allowing biomolecules to pass through, so that substance exchange and signal transmission between the first cell accommodating unit and the second cell accommodating unit are realized. According to the invention, an in-vitro model with high physiological correlation and accurate prediction is brought by accurately reproducing spatial tissues and dynamic microenvironments of organs, and a tissue and blood vessel interface is successfully simulated through combination of a separated co-culture structure and a dynamic fluid perfusion system, so that cells can be self-organized into a functionalized three-dimensional structure with polarity, and the functional three-dimensional structure with polarity is formed. Therefore, the sensitivity and the specificity which are far superior to those of a traditional model are realized in tests of drug hepatotoxicity and the like.

The invention relates to the technical field of medicine preparation, in particular to a medicine composition based on mesenchymal stem cells and application of the medicine composition. And a pharmaceutically acceptable carrier. The pharmaceutical composition based on the mesenchymal stem cells has the following beneficial effects that the inflammatory response and fibrosis process of the focus of alveolar coccosis can be remarkably inhibited through the immune regulation function of the mesenchymal stem cells, and meanwhile, the cytokines secreted by the mesenchymal stem cells can directly inhibit the vitality of the protoscolex and the cell proliferation of the hair growth layer; the synergistic treatment effect of parasite killing, immunoregulation and tissue repair is realized; when the traditional Chinese medicine composition is combined with the existing anti-parasitic medicine, the dosage can be reduced, the hepatotoxicity can be reduced, the traditional Chinese medicine composition has remarkable advantages especially for patients with advanced diffuse lesions and postoperative recurrence, and a novel treatment strategy with high efficiency and low toxicity is provided for alveolar coccosis.

The application discloses application of a GPR120 agonist in preventing or treating intestinal-liver immunological injury induced by poultry acetochlor poisoning. According to the intestinal-liver toxicity of chicken acetochlor, the normal expression of G protein-coupled receptor 120 is mainly changed. Subsequently, programmed cell death occurs in the intestinal tract and the liver, and a large amount of inflammatory factor release is caused; the intestinal-liver axis immunological injury is improved by activating the G protein-coupled receptor 120 in vivo and in vitro, so as to rescue the chicken acetochlor poisoning reaction. The application provides a prevention and treatment basis for poultry acetochlor poisoning immunological injury diseases, provides medical data for developing poultry immunological activity drugs or supplements, and also provides more technical means for developing and utilizing environment-friendly, efficient, targeted and slow-release new veterinary drug preparations.

The present invention discloses a drug for treating crizotinib-induced liver toxicity by targeting the SQLE gene or protein, belonging to the field of pharmaceutical technology. The drug reverses crizotinib-induced liver toxicity by downregulating the expression of the SQLE gene or the accumulation of SQLE protein. By downregulating SQLE, the present invention can effectively reverse crizotinib-induced apoptosis of hepatocytes, revealing that the SQLE gene is a key gene for crizotinib-induced liver injury and providing a new preventive and therapeutic target for intervening in crizotinib-induced hepatotoxicity. The present invention proposes that SQLE can be degraded through the autophagy pathway, providing a new direction for currently searching for intervention strategies for drug-induced hepatotoxicity and to a certain extent solving the current situation of few clinically available intervention drugs and single mechanisms. The intervention drug reverses crizotinib-induced liver toxicity by downregulating SQLE, expanding the clinical application value of crizotinib.

The invention relates to the technical field of biological medicines, in particular to a psoralen derivative and application thereof in preparation of a medicine for treating rheumatoid arthritis. According to the derivative, through an ester prodrug strategy, psoralen C8 / C5 hydroxyl and a non-steroidal anti-inflammatory drug are coupled to obtain a double-pharmacophore molecule. According to the invention, the problems of poor lipid solubility and high hepatotoxicity of psoralen are solved through an ester prodrug design strategy, a high-efficiency and low-toxicity novel drug candidate is provided for RA treatment, and the prepared psoralen derivative can effectively treat rheumatoid arthritis and complications thereof, and can significantly improve arthropathy caused by RA.

The invention discloses a medicine for treating drug-induced liver injury by taking a DDR1 gene or protein as a target spot, and belongs to the technical field of medicines. The drug-induced liver injury is caused by abnormal activation or accumulation of DDR1 protein, and the pathological characteristics of the drug-induced liver injury comprise nesting apoptosis of liver cells. The invention discloses that DDR1 is a key molecular target for inducing hepatotoxicity by the Platinib for the first time, and the Platinib can lead to obvious increase of DDR1 protein and phosphorylation level thereof at a treatment concentration, so that cell-ECM and cell-cell adhesion are damaged, and anoikis is activated. By inhibiting the expression of the DDR1 gene or inhibiting the activity and accumulation of the DDR1 protein, the hepatocyte apoptosis caused by the Platinib can be effectively reversed. The invention provides a new molecular target for intervening in the induced hepatotoxicity of the prilatinib, and provides a new strategy for clinically and safely treating RET fusion positive tumors by preparing a drug for preventing or treating drug-induced liver injury by utilizing a substance for inhibiting the targeted DDR1.

The present application relates to a kind of in vitro 3D liver model and enterohepatic co-culture model and its establishment method and application, belong to the technical field of drug evaluation.The method includes the following steps: cell culture: HepaRG cell and human hepatic stellate cell are respectively carried out cell culture, standby;Cell induction: the above-mentioned HepaRG cell is seeded in culture flask and is carried out cell culture, after HepaRG cell adherent growth reaches predetermined quantity, it is replaced with induction medium and is carried out induction culture, and the induced HepaRG cell is obtained, standby;Model construction: the induced HepaRG cell and human hepatic stellate cell are made into mixed cell suspension, seed on predetermined carrier, culture, obtain the microtissue with the three-dimensional structure of liver nodule, i.e. 3D liver model.The model has the three-dimensional structure of liver nodule microtissue of liver, can well simulate the actual physiological condition of in-vivo liver, to accurately predict the liver toxicity of drug.

The invention provides an application of selenium-rich probiotics in preparation of a preparation for treating fluoxetine-induced liver injury, and relates to the technical field of biological medicine, the application is characterized in that Se-BL is obtained by reducing sodium selenite through ascorbic acid and modifying the surface of bifidobacterium longum, and nano-scale selenium dots are formed. The preparation plays a role through dual mechanisms: active oxygen (ROS) is directly removed, an Nrf2 pathway is activated, and the liver oxidation resistance (GSH, SOD) is improved; the traditional Chinese medicine composition is capable of inhibiting NF-kappa B inflammation signal channels, reducing proinflammatory factors (TNF-alpha and IL-6) and synchronously regulating intestinal flora so as to enhance the intestinal barrier function. Experiments prove that the traditional Chinese medicine composition can remarkably reduce the level of serum transaminase (ALT / AST / ALP) and relieve liver tissue necrosis and lipid peroxidation damage (MDA), the dosage form of the traditional Chinese medicine composition is an oral preparation, and each dose of the traditional Chinese medicine composition contains 1 * 10 <-1 > * 10 <-1 > CFU of Se-BL viable bacteria. The selenium-modified probiotics are used for antagonizing hepatotoxicity of mental drugs for the first time, and an innovative therapy is provided for fluoxetine-induced drug-induced liver injury (DILI) and acute hepatic failure (ALF).